1. Home
  2. CCM vs FEMY Comparison

CCM vs FEMY Comparison

Compare CCM & FEMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Concord Medical Services Holdings Limited

CCM

Concord Medical Services Holdings Limited

N/A

Current Price

$2.94

Market Cap

21.3M

Sector

Health Care

ML Signal

N/A

FEMY

Femasys Inc.

N/A

Current Price

$2.10

Market Cap

22.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CCM
FEMY
Founded
1997
2004
Country
China
United States
Employees
N/A
N/A
Industry
Medical/Nursing Services
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
21.3M
22.4M
IPO Year
2009
2021

Fundamental Metrics

Financial Performance
Metric
CCM
FEMY
Price
$2.94
$2.10
Analyst Decision
Buy
Analyst Count
0
3
Target Price
N/A
★ $14.33
AVG Volume (30 Days)
11.3K
★ 67.0K
Earning Date
10-06-2026
11-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 44.71
EPS
★ N/A
N/A
Revenue
N/A
★ $2,293,313.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$328.45
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 40.77
52 Week Low
$3.18
$0.29
52 Week High
$6.96
$6.29

Technical Indicators

Market Signals
Indicator
CCM
FEMY
Relative Strength Index (RSI) N/A 37.40
Support Level N/A $0.41
Resistance Level N/A $3.21
Average True Range (ATR) 0.00 0.17
MACD 0.00 -0.04
Stochastic Oscillator 0.00 27.12

Price Performance

Historical Comparison
CCM
FEMY

About CCM Concord Medical Services Holdings Limited

Concord Medical Services Holdings Ltd operates radiotherapy and diagnostic imaging centers in China. The company is involved in the leasing of radiotherapy and diagnostic imaging equipment, provision of management services to hospitals, medicine sales, and provision of premium cancer and proton treatment services. The company has two operating segments, including network and hospital. Geographically, the company derives revenue from PRC.

About FEMY Femasys Inc.

Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.

Share on Social Networks: